Human RCT
Mensch
Lowers elevated growth-hormone and IGF-1 levels in acromegaly.
What does NOT follow: Approved indication; use in healthy people is not studied and not intended.
Peptide entry · Research other
Lanreotid
Lanreotide · Somatuline · Somatuline Autogel
Highest evidence
Human RCT
Studies recorded
1· 1 in humans
Legal status · US
PrescriptionScientific context only. Not medical advice, not a recommendation to use.
At a glance
Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours.
Researched for
AcromegalyNeuroendocrine tumorsGH/IGF-1 suppression
Official status
US: Prescription
FDA-approved (2007) for acromegaly and neuroendocrine tumours.
01
Mechanism of action
Lanreotide activates somatostatin receptors (chiefly SSTR2, additionally SSTR5), thereby suppressing the release of growth hormone, IGF-1 and various gastrointestinal and neuroendocrine hormones. It is metabolically far more stable than natural somatostatin.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
03
What the studies show
Human RCT
Mensch
Caplin ME, Pavel M, Ćwikła JB, et al. 2014
In a randomized trial, prolonged progression-free survival in enteropancreatic neuroendocrine tumours (CLARINET).
What does NOT follow: Specific tumour population; not transferable to other diseases or contexts.
04
Where studies disagree
Open question
Are lanreotide and octreotide clinically interchangeable?
POSITION A
Both are SSTR2/5 analogs with broadly similar efficacy and side-effect profiles.
POSITION B
Differences in formulation, pharmacokinetics and dosing interval can influence the choice case-by-case; head-to-head trials are limited.
CURRENT STATE · Regarded as largely therapeutically equivalent; selection is individualised.
05
Pharmacokinetics
No robust pharmacokinetic human data available. A model curve is not invented.
06d
Safer use & risks
Risk notes for harm reduction — descriptive, not a usage or dosing guide.
This substance is approved (in at least one country) — use belongs in medical hands, within the approved indication and a physician-set dose.
Online numbers are not a benchmark
Amounts from TikTok, YouTube and forums are mostly imitation rather than data — and are often wrongly derived from animal studies (µg/kg). Not a reliable benchmark for humans.
Sterility & infection risk
Injection solutions prepared or stored non-sterile carry an infection and abscess risk. Contamination is common with grey-market product.
Unknown product quality
Research-/grey-market product is not quality-tested: identity, purity and actual content are often unknown, and counterfeits occur.
Mind interactions
Combinations with medications or pre-existing conditions can carry risks (see the Interactions section). Clarify with a doctor beforehand.
Warning signs — seek medical help
With persistent pain, redness/swelling at the injection site, fever, shortness of breath, racing heart, chest pain or allergic reactions, seek medical help immediately.
A doctor, not a forum
Concrete questions about use and amount belong in a conversation with a doctor — not in a comment thread.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Human trial
Gallstones / gallbladder sludge
A class effect of somatostatin analogs from reduced gallbladder contraction; monitored in trials.
häufig
Human trial
Gastrointestinal complaints (diarrhea, abdominal pain, nausea)
Usually at the start of therapy; a factual report, not a usage instruction.
häufig
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
11
Legal status by country
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
- 1Enter the vial's substance amount (printed on the label).
- 2Enter how much solvent you add.
- 3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.
14
Study register
Human RCTRandomised controlled trialn = 204
Caplin ME, Pavel M, Ćwikła JB, et al. · 2014
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors (CLARINET)
SamplePatients with metastatic, well/moderately differentiated enteropancreatic neuroendocrine tumours.
EndpointProgression-free survival.
Concrete results
Progression-free survival (median)
nicht erreicht vs. 18,0 Monate
HR 0,47 vs. Placebo · 96 Wochen
Progression-free at 96 weeks
65,1% vs. 33%
vs. Placebo · 96 Wochen
Findings:Lanreotide significantly prolonged progression-free survival versus placebo.
Limitations:Narrowly defined tumour population; an overall-survival benefit was not primarily shown in this trial.
15
Sources & method
Last reviewed
2026-06-11
Get new studies on Lanreotid
Science only, no sales. Unsubscribe anytime.
We store your email only for the newsletter. Unsubscribe anytime. Privacy